Peptide Cancer Vaccine Forces Tumors to Reveal Themselves to the Immune System Again | Research

The takeaway

A peptide-based cancer vaccine restores MHC-I expression on immune-evading nasopharyngeal carcinoma cells by reactivating the silenced NLRC5 gene, making tumors visible to T cell attack.

63% of tumors had reduced MHC-I
While NPC is considered 'immune-hot,' the majority of tumors had silenced their antigen presentation — but peptide vaccine-trained T cells were able to reverse this silence and restore immune visibility.

What the researchers found

A peptide-based cancer vaccine overcomes immune evasion in nasopharyngeal carcinoma by restoring the cell's antigen presentation machinery. Peptide-trained T cells upregulated NLRC5 (the most downregulated gene in NPC tumors), restored MHC-I expression, and enhanced tumor cell killing — even in cells where NLRC5 had been experimentally knocked down. The vaccine approach was validated in a mouse tumor model, showing consistent restoration of antigen presentation gene expression in vivo.

Why it matters

Many cancers escape the immune system by hiding their surface markers (MHC-I), making them invisible to T cells. This study shows that a peptide vaccine can actually force cancer cells to re-expose these markers by reactivating the silenced NLRC5 gene. This is particularly important because it means peptide vaccines could work even against tumors that have evolved to evade immunity — a major barrier to immunotherapy success.

The numbers in context

42 NPC tumors + 4 non-NPC tissues analyzed · 17-gene APM signature · NLRC5 most downregulated · MHC-I downregulated in 63% of tumors · 35 tumors by IHC · siRNA NLRC5 knockdown reversed by peptide-trained T cells · validated in vivo

How the study worked

Researchers analyzed 42 NPC tumors for antigen presentation machinery (APM) gene expression using a 17-gene signature. MHC-I expression was assessed by immunohistochemistry in 35 tumors. Peptide-trained T cells were co-cultured with NPC cells to study APM gene modulation. A siRNA-mediated NLRC5 knockdown model tested whether vaccine-induced T cells could reverse immune evasion. In vivo validation used a poorly immunogenic mouse tumor model.

Who was studied

42 NPC tumors, 35 tumors for IHC, NPC cell lines, and mouse tumor model

What this study cannot tell us

The in vitro co-culture system is simplified compared to the tumor microenvironment. The study focused on nasopharyngeal carcinoma and may not apply to all cancer types with MHC-I downregulation. The specific peptide antigens used for T cell training were not detailed in the abstract. Long-term durability of the restored antigen presentation and sustained anti-tumor response were not assessed.

How to read the evidence

This study combines human tumor gene expression analysis, in vitro mechanistic experiments with NPC cell lines and siRNA models, and in vivo mouse validation. The multi-level evidence is compelling, though translation to human clinical outcomes requires clinical trials.

When this study was published

Published in 2025, this study addresses a current challenge in cancer immunotherapy — how to make immune-cold or immune-evasive tumors responsive to treatment.

The bigger picture

Immune evasion through MHC-I downregulation is a major barrier to immunotherapy success across many cancer types. This study demonstrates that peptide vaccines can actively counteract this evasion — not just generating anti-tumor T cells, but fundamentally changing the tumor's biology to make it more immunogenic. If broadly applicable, this could make peptide vaccines effective even against tumors that currently resist checkpoint inhibitors and other immunotherapies.

Questions still open

Could this peptide vaccine approach restore MHC-I expression in other cancer types with APM downregulation?
Would combining the peptide vaccine with checkpoint inhibitors produce synergistic anti-tumor effects?
What mechanism do peptide-trained T cells use to upregulate NLRC5 in tumor cells — is it cytokine-mediated?

Common questions

How do cancer cells hide from the immune system?

Cancer cells can turn off the expression of MHC-I molecules — surface tags that display fragments of their internal proteins to T cells. Without MHC-I, T cells can't recognize the cancer cell as abnormal. In this study, 63% of nasopharyngeal carcinoma tumors had reduced MHC-I because a key regulatory gene (NLRC5) was silenced.

How does a peptide vaccine reverse this hiding?

The peptide vaccine trains T cells to recognize specific tumor protein fragments. When these trained T cells encounter cancer cells, they release signaling molecules (likely cytokines like interferon-γ) that force the cancer cells to reactivate NLRC5 and restore MHC-I expression. This turns the cancer's hiding strategy against itself — the immune interaction triggered by the vaccine actually makes the tumor more visible to further immune attack.

Read the original research

Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5.

Journal of translational medicine, 23(1), 1414

View on PubMed ↗Publisher’s paper ↗

Citation

Gan, Chai Phei; Kok, Sau Yee; Lee, Bernard Kok Bang; Zulaziz, Natasha; Cheong, Sok Ching; Savelyeva, Natalia; Lim, Kue Peng. (2025). Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5.. Journal of translational medicine, 23(1), 1414. https://doi.org/10.1186/s12967-025-07418-x